Skip to main content
Top
Published in: International Journal of Hematology 6/2015

01-06-2015 | Original Article

Analysis of clinical characteristics and prognostic factors for angioimmunoblastic T-cell lymphoma

Authors: Yoshihiro Kameoka, Naoto Takahashi, Shigeki Itou, Masaaki Kume, Hideyoshi Noji, Yuichi Kato, Yoshikazu Ichikawa, Osamu Sasaki, Mutsuhito Motegi, Atsushi Ishiguro, Hiroyuki Tagawa, Kenichi Ishizawa, Yoji Ishida, Ryo Ichinohasama, Hideo Harigae, Kenichi Sawada

Published in: International Journal of Hematology | Issue 6/2015

Login to get access

Abstract

Angioimmunoblastic T-cell lymphoma (AITL) is a distinct peripheral T-cell lymphoma entity exhibiting peculiar clinical features and poor prognosis. Its clinical characteristics and prognostic factors are not well established. To clarify the clinical characteristics and prognostic features of AITL, we conducted a multicenter, retrospective study. Fifty-six patients were enrolled. The median patient age was 68 years. Immunohistochemical examinations of tumor cells showed positivity for CD10 and T-cell markers, and chromosomal examination detected several types of abnormalities. More than 80 % of patients show advanced disease at diagnosis and poor prognostic scores. A high proportion of patients showed accompanying B symptoms, splenomegaly, and hepatomegaly at diagnosis. The 5-year overall survival (OS) rate was 48 % and progression-free survival was 25 %. Univariate analysis revealed higher age, fever, poor performance status, anemia, and low albumin level to be poor prognostic factors for OS. In addition to these factors, both IPI and PIT were also predictive of OS. Multivariate analysis indicated only a low level of serum albumin to be a significant prognostic factor for OS. Serum albumin may be one of the important prognostic factors for AITL. Further investigation is needed to confirm these results.
Literature
1.
go back to reference Mourad N, Mounier N, Brière J, Raffoux E, Delmer A, Feller A, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trials. Blood. 2008;111:4463–70.PubMedCentralPubMedCrossRef Mourad N, Mounier N, Brière J, Raffoux E, Delmer A, Feller A, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trials. Blood. 2008;111:4463–70.PubMedCentralPubMedCrossRef
2.
go back to reference Rüdiger T, Weisenburger DD, Anderson JR, Armitage JO, Diebold J, MacLennan KA, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol. 2002;13:140–9.PubMedCrossRef Rüdiger T, Weisenburger DD, Anderson JR, Armitage JO, Diebold J, MacLennan KA, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol. 2002;13:140–9.PubMedCrossRef
3.
go back to reference de Leval L, Rickman DS, Thielen C, Reynies Ad, Huang YL, Delsol G, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007;109:4952–63.PubMedCrossRef de Leval L, Rickman DS, Thielen C, Reynies Ad, Huang YL, Delsol G, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007;109:4952–63.PubMedCrossRef
4.
go back to reference Attygalle A, Al-Jehani R, Diss TC, Munson P, Liu H, Du MQ, et al. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood. 2002;99:627–33.PubMedCrossRef Attygalle A, Al-Jehani R, Diss TC, Munson P, Liu H, Du MQ, et al. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood. 2002;99:627–33.PubMedCrossRef
5.
go back to reference Dupuis J, Boye K, Martin N, Copie-Bergman C, Plonquet A, Fabiani B, et al. Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol. 2006;30:490–4.PubMedCrossRef Dupuis J, Boye K, Martin N, Copie-Bergman C, Plonquet A, Fabiani B, et al. Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol. 2006;30:490–4.PubMedCrossRef
6.
go back to reference Dorfman DM, Brown JA, Shahsafaei A, Freeman GJ. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2006;30:802–10.PubMedCentralPubMedCrossRef Dorfman DM, Brown JA, Shahsafaei A, Freeman GJ. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2006;30:802–10.PubMedCentralPubMedCrossRef
7.
go back to reference Federico M, Rudiger T, Bellei M, Nathwani BN, Luminari S, Coiffier B, et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma:analysis of the international peripheral T-cell lymphoma project. J Clin Oncol. 2013;31:240–6.PubMedCentralPubMedCrossRef Federico M, Rudiger T, Bellei M, Nathwani BN, Luminari S, Coiffier B, et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma:analysis of the international peripheral T-cell lymphoma project. J Clin Oncol. 2013;31:240–6.PubMedCentralPubMedCrossRef
8.
go back to reference Frizzera G, Moran EM, Rappaport H. Angio-immunoblastic lymphadenopathy with dysproteinaemia. Lancet. 1974;1:1070–3.PubMedCrossRef Frizzera G, Moran EM, Rappaport H. Angio-immunoblastic lymphadenopathy with dysproteinaemia. Lancet. 1974;1:1070–3.PubMedCrossRef
9.
go back to reference Siegert W, Agthe A, Griesser H, Schwerdtfeger R, Brittinger G, Engelhard M, et al. Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group. Ann Intern Med. 1992;117:364–70.PubMedCrossRef Siegert W, Agthe A, Griesser H, Schwerdtfeger R, Brittinger G, Engelhard M, et al. Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group. Ann Intern Med. 1992;117:364–70.PubMedCrossRef
10.
go back to reference Siegert W, Nerl C, Meuthen I, Zahn T, Brack N, Lennert K, et al. Recombinant human interferon-alpha in the treatment of angioimmunoblastic lymphadenopathy:results in 12 patients. Leukemia. 1991;5:892–5.PubMed Siegert W, Nerl C, Meuthen I, Zahn T, Brack N, Lennert K, et al. Recombinant human interferon-alpha in the treatment of angioimmunoblastic lymphadenopathy:results in 12 patients. Leukemia. 1991;5:892–5.PubMed
11.
go back to reference Advani R, Warnke R, Sikic BI, Horning S. Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine. Ann Oncol. 1997;8:601–3.PubMedCrossRef Advani R, Warnke R, Sikic BI, Horning S. Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine. Ann Oncol. 1997;8:601–3.PubMedCrossRef
12.
go back to reference Pautier P, Devidas A, Delmer A, Dombret H, Sutton L, Zini JM, et al. Angioimmunoblastic-like T-cell non Hodgkin’s lymphoma: outcome after chemotherapy in 33 patients and review of the literature. Leuk Lymphoma. 1999;32:545–52.PubMed Pautier P, Devidas A, Delmer A, Dombret H, Sutton L, Zini JM, et al. Angioimmunoblastic-like T-cell non Hodgkin’s lymphoma: outcome after chemotherapy in 33 patients and review of the literature. Leuk Lymphoma. 1999;32:545–52.PubMed
13.
go back to reference Siegert W, Nerl C, Agthe A, Engelhard M, Brittinger G, Tiemann M, et al. Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma:prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group. Ann Oncol. 1995;6:659–64.PubMed Siegert W, Nerl C, Agthe A, Engelhard M, Brittinger G, Tiemann M, et al. Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma:prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group. Ann Oncol. 1995;6:659–64.PubMed
14.
go back to reference A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987–94. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987–94.
15.
go back to reference Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103:2474–9.PubMedCrossRef Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103:2474–9.PubMedCrossRef
16.
go back to reference Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.PubMed Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.PubMed
17.
go back to reference Cheson BD, Pfistner B, Juweid ME, Shipp MA, Fisher RI, Connors JM, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.PubMedCrossRef Cheson BD, Pfistner B, Juweid ME, Shipp MA, Fisher RI, Connors JM, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.PubMedCrossRef
18.
go back to reference Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRef Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRef
19.
go back to reference Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–70.PubMed Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–70.PubMed
20.
go back to reference Tokunaga T, Shimada K, Yamamoto K, Chihara D, Ichihashi T, Oshima R, et al. Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan. Blood. 2012;119:2837–43.PubMedCrossRef Tokunaga T, Shimada K, Yamamoto K, Chihara D, Ichihashi T, Oshima R, et al. Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan. Blood. 2012;119:2837–43.PubMedCrossRef
21.
go back to reference Watanabe T, Kinoshita T, Itoh K, Yoshimura K, Ogura M, Kagami Y, et al. Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas. Leuk Lymphoma. 2010;51:813–21.PubMedCrossRef Watanabe T, Kinoshita T, Itoh K, Yoshimura K, Ogura M, Kagami Y, et al. Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas. Leuk Lymphoma. 2010;51:813–21.PubMedCrossRef
22.
go back to reference Lee SS, Rüdiger T, Odenwald T, Roth S, Starostik P, Müller-Hermelink HK. Angioimmunoblastic T cell lymphoma is derived from mature T-helper cells with varying expression and loss of detectable CD4. Int J Cancer. 2003;103:12–20.PubMedCrossRef Lee SS, Rüdiger T, Odenwald T, Roth S, Starostik P, Müller-Hermelink HK. Angioimmunoblastic T cell lymphoma is derived from mature T-helper cells with varying expression and loss of detectable CD4. Int J Cancer. 2003;103:12–20.PubMedCrossRef
23.
go back to reference Pangalis GA, Moran EM, Nathwani BN, Zelman RJ, Kim H, Rappaport H. Angioimmunoblastic lymphadenopathy. Long-term follow-up study. Cancer. 1983;52:318–21.PubMedCrossRef Pangalis GA, Moran EM, Nathwani BN, Zelman RJ, Kim H, Rappaport H. Angioimmunoblastic lymphadenopathy. Long-term follow-up study. Cancer. 1983;52:318–21.PubMedCrossRef
24.
go back to reference Archimbaud E, Coiffier B, Bryon PA, Vasselon C, Brizard CP, Viala JJ. Prognostic factors in angioimmunoblastic lymphadenopathy. Cancer. 1987;59:208–12.PubMedCrossRef Archimbaud E, Coiffier B, Bryon PA, Vasselon C, Brizard CP, Viala JJ. Prognostic factors in angioimmunoblastic lymphadenopathy. Cancer. 1987;59:208–12.PubMedCrossRef
25.
go back to reference Lee SM, Ryder WD, Clemons MJ, Morgenstern GR, Chang J, Scarffe JH, et al. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin’s lymphoma. Bone Marrow Transpl. 1999;24:271–7.CrossRef Lee SM, Ryder WD, Clemons MJ, Morgenstern GR, Chang J, Scarffe JH, et al. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin’s lymphoma. Bone Marrow Transpl. 1999;24:271–7.CrossRef
26.
go back to reference Federico M, Vitolo U, Zinzani PL, Chisesi T, Clò V, Bellesi G, et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi Blood. 2000;95:783–9. Federico M, Vitolo U, Zinzani PL, Chisesi T, Clò V, Bellesi G, et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi Blood. 2000;95:783–9.
27.
go back to reference Ibrahim EM, Ezzat AA, El-Weshi AN, Martin JM, Khafaga YM, Al Rabih W, et al. Primary intestinal diffuse large B-cell non-Hodgkin’s lymphoma: clinical features, management, and prognosis of 66 patients. Ann Oncol. 2001;12:53–8.PubMedCrossRef Ibrahim EM, Ezzat AA, El-Weshi AN, Martin JM, Khafaga YM, Al Rabih W, et al. Primary intestinal diffuse large B-cell non-Hodgkin’s lymphoma: clinical features, management, and prognosis of 66 patients. Ann Oncol. 2001;12:53–8.PubMedCrossRef
28.
go back to reference Katsuya H, Yamanaka T, Ishitsuka K, Utsunomiya A, Sasaki H, Hanada S, et al. Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. J Clin Oncol. 2012;30:1635–40.PubMedCrossRef Katsuya H, Yamanaka T, Ishitsuka K, Utsunomiya A, Sasaki H, Hanada S, et al. Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. J Clin Oncol. 2012;30:1635–40.PubMedCrossRef
29.
go back to reference Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med. 1998;339:1506–14.PubMedCrossRef Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med. 1998;339:1506–14.PubMedCrossRef
Metadata
Title
Analysis of clinical characteristics and prognostic factors for angioimmunoblastic T-cell lymphoma
Authors
Yoshihiro Kameoka
Naoto Takahashi
Shigeki Itou
Masaaki Kume
Hideyoshi Noji
Yuichi Kato
Yoshikazu Ichikawa
Osamu Sasaki
Mutsuhito Motegi
Atsushi Ishiguro
Hiroyuki Tagawa
Kenichi Ishizawa
Yoji Ishida
Ryo Ichinohasama
Hideo Harigae
Kenichi Sawada
Publication date
01-06-2015
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 6/2015
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-015-1763-7

Other articles of this Issue 6/2015

International Journal of Hematology 6/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine